Details

Autor(en) / Beteiligte

• 정혜웅
• 오창민
• 진효언
• 정종화

Titel

2023년 FDA 승인 펩타이드 의약품

Ist Teil von

• 약 학 회 지, 2024, 68(2), , pp.79-83

Ort / Verlag

대한약학회

Erscheinungsjahr

2024

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Peptide drugs generally show high performance in terms of safety, target affinity, and efficacy, but havelimitations such as low bioavailability and short half-life. To improve this, new synthetic and analytical techniques havebeen developed, and the global market for peptide drugs has made great strides in the past few years, with novel peptidedrugs being applied to multiple therapeutic areas. In line with this trend, 5 out of 55 new molecular entities (NMEs)approved by the FDA in the year 2023 were peptide drugs, which is an increasing trend in the last few years. In thisreview article, we will discuss the mechanisms of action and clinical indications, chemical structure and design, andpharmacokinetic perspectives of 6 FDA-approved peptide drugs in 2023 including 5 NMEs. KCI Citation Count: 0